AbSci’s $125 Million Crossover Financing

Goodwin Procter LLP advised AbSci on the deal.

AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, announced a $125 million crossover financing. The round was co-led by existing investors Casdin Capital and Redmile Group, with participation from new investors Fidelity Management and Research Company LLC, D1 Capital Partners, Perceptive Advisors, aMoon Edge, and Irving Investors, as well as other existing investors including ArrowMark Partners.

Proceeds will support AbSci’s continued growth, including research and development activities and other strategic investments. Key areas of focus are integration and training of the Denovium Engine™ deep learning artificial intelligence platform AbSci acquired in January 2021, and ongoing expansion of core discovery capabilities including non-standard amino acid technologies.

AbSci is a leading synthetic biology company that translates ideas into drugs with a revolutionary platform technology that reinvents the biopharmaceutical drug discovery process.

The Goodwin team was led by Maggie Wong (Picture) and Kingsley Taft and included Mulon Luo and Temesgen Woldezion.



Involved fees earner: Mulon Luo – Goodwin Procter; Kingsley Taft – Goodwin Procter; Maggie Wong – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: AbSci;

Author: Martina Bellini